Kisspeptin-10

What the academic literature shows

• · Kisspeptin and its receptor (KISS1R/GPR54) were identified as essential regulators of the hypothalamic-pituitary-gonadal (HPG) axis following the discovery that GPR54 loss-of-function mutations cause hypogonadotropic hypogonadism in humans and rodents.
• · The Dhillo research group at Imperial College London has published multiple peer-reviewed studies examining kisspeptin administration in human participants, including studies of GnRH pulse modulation in healthy volunteers and in specific patient populations. These are legitimate NHS-affiliated academic studies conducted under appropriate ethics approval.
• · Animal studies across multiple species have confirmed that kisspeptin signalling is required for normal puberty onset and reproductive cyclicity.
• · Human studies have examined Kisspeptin-10 as a research tool to probe GnRH pulse generation in physiological and pathophysiological conditions. This is mechanistic research, not clinical efficacy research for a licensed therapeutic product.
• · No randomised controlled trial has led to a regulatory submission for a kisspeptin-based licensed medicine in the UK or any other jurisdiction as of this editorial date.
• · The existence of peer-reviewed UK academic research is notable context for this compound relative to other research peptides. However, academic research conducted under ethics approval is not the same as a licensed pharmaceutical product.

Evidence quality assessment: the academic literature for Kisspeptin-10 is of higher methodological quality than many research peptides, owing to the involvement of UK NHS-affiliated institutions. Nonetheless, the compound remains unlicensed and the human studies are mechanistic research tools, not clinical efficacy trials for an approved indication.